Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
160 participants
INTERVENTIONAL
2016-11-30
2019-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intrauterine Injection of Human Chorionic Gonadotropin Before Embryo Transfer in Women With Previous IVF Failure
NCT02329197
The Value of Addition of Human Menopausal Gonadotropin Drug Following Oocytes Retrieval in IVF Cycles
NCT03209687
Three Small Doses of HCG Versus Booster Dose of HCG on Ovum Pickup Day
NCT02397551
Human Chorionic Gonadotrophin & Trigger
NCT02264847
Human Chorionic Gonadotrophin in an Antagonist Protocol
NCT01833858
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Human chorionic gonadotrophin group
Patients will receive Human chorionic gonadotrohpin injection 5000 unit
Recombinant Human Chorionic Gonadotrophin
250 unit intramuscular
Human chorionic gonadotrophin + agonist group
patients will receive both Human chorionic gonadotrophin (2500 unit) and gonadotrophin releasing hormone agonist 1mg leuprolide acetate
human chorionic gonadotrophin + gonadotrophin releasing hormone agonist
250 unit intramuscular + 1 mg subcutaneous
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Recombinant Human Chorionic Gonadotrophin
250 unit intramuscular
human chorionic gonadotrophin + gonadotrophin releasing hormone agonist
250 unit intramuscular + 1 mg subcutaneous
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. first intracytoplasmic injection trial
3. Body mass index:18-30.
5-Antral follicular count: more than 5 follicles in one ovary 6-normal, mild or moderate male factor infertility. 7- Antimullerian hormone \>1 ng/ml
Exclusion Criteria
2. Body mass index more than 29.
3. Patients with endometriosis .
4. Antimullerian hormone \< 1 ng/ml
20 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Mohamed Abbas
dr
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ahmed Abbas
Assiut, Cairo Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FM-ART
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.